Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138147 | 0.81 | HSD17B10 (0.50) | HSD17B10SLC6A9KDM4EALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL19148315 | 0.79 | HSD17B10 (0.48) | HSD17B10SLC6A9KDM4EALDH1A1CYP1A2 | |
| Tetraxetan SCHEMBL2635294 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9GAAS1PR1KDM4E | |
| Tetraxetan SCHEMBL2017956 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9GAAS1PR1KDM4E | |
| SCHEMBL6744121 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9GAAS1PR1KDM4E | |
| SCHEMBL6848102 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9GAAS1PR1KDM4E | |
| Tetraxetan SCHEMBL18018 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9GAAS1PR1KDM4E | |
| SCHEMBL321989 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9GAAS1PR1KDM4E | |
| SCHEMBL173508 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9GAAS1PR1KDM4E | |
| SCHEMBL3503521 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9GAAS1PR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121046-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023218203-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| US-20190023733-A1 | AMINE DERIVATIVES OF LUPANES WITH HIV MATURATION INHIBITORY ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| US-20140221361-A1 | C-19 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| US-20080200460-A1 | Chemical Compounds | BROWN DEARG | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221361-A1 | C-19 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, CYP4A22 | HSD17B10 77/4885SLC6A9 4023/4885GAA 987/4885 |
| US-20080200460-A1 | Chemical Compounds | CCR5, CXCR4, CXCR5 | HSD17B10 2020/4885SLC6A9 2849/4885GAA 4767/4885 |
| US-20190023733-A1 | AMINE DERIVATIVES OF LUPANES WITH HIV MATURATION INHIBITORY ACTIVITY | LSS, FURIN, CYP51A1 | HSD17B10 785/4885SLC6A9 1346/4885GAA 215/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | HSD17B10 1951/4885SLC6A9 1083/4885GAA 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.